Background: Neurotransmitter deficits and spatial associations among neurotransmitter distribution, brain activity, and clinical features in Parkinson's disease (PD) remain unclear. Better understanding of neurotransmitter impairments in PD may provide potential therapeutic targets. Therefore, we aimed to investigate the spatial relationship between PD-related patterns and neurotransmitter deficits.
View Article and Find Full Text PDFQuant Imaging Med Surg
December 2023
There is escalating interest in composting of post-consumption food waste (PCFW) to recycle nutrients and mitigate pollution by inappropriate disposal. The present study aimed to evaluate the performance of bioaugmentation to composting of PCFW, which is in difficulties caused by high sugar, protein and gross lipid content. Inoculation of the microbial consortium effectively induced rapid temperature and pH rising, which led to OM reduction rate at 25.
View Article and Find Full Text PDF(1) Background: Inflammatory bowel diseases are complex and multifactorial disorders of unknown etiology. The extravasation of activated leukocytes is a critical step in the pathogenesis of these diseases. Leukocyte integrin Mac-1 (αβ; CD11b/CD18) is crucial for the extravasation of myeloid cells, and a novel activation-specific anti-Mac-1 Designed Ankyrin Repeat protein (DARPin F7) is a promising therapeutic agent for inflammatory diseases.
View Article and Find Full Text PDFIntroduction: Despite verifying proton magnetic resonance spectroscopy (H-MRS) for focal localization in magnetic resonance imaging (MRI)-negative temporal lobe epilepsy (TLE), it is necessary to illustrate metabolic changes and screen for effective biomarkers for monitoring therapeutic effect. We used H-MRS to investigate the role of metabolic levels in MRI-negative TLE.
Materials And Methods: Thirty-seven patients ( = 37, 14 women) and 20 healthy controls ( = 20, 11 women) were investigated by H-MRS.
Background: 125I BT is an effective radiotherapy for prostate cancer. However, comparison data of GI and GU toxicities between BT, BT + EBRT, and EBRT-alone patient groups is limited.
Objective: To define the GI and GU toxicities in prostate cancer to prevent adverse events after treatment.